Augmentin Tablets

국가: 오스트레일리아

언어: 영어

출처: Department of Health (Therapeutic Goods Administration)

유효 성분:

amoxicillin trihydrate, Quantity: 286.9 mg (Equivalent: amoxicillin trihydrate, Qty 250 mg); potassium clavulanate, Quantity: 149.5 mg (Equivalent: clavulanic acid, Qty 125 mg)

제공처:

Aspen Pharmacare Australia Pty Ltd

약제 형태:

Tablet, film coated

구성:

Excipient Ingredients: colloidal anhydrous silica; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; dimeticone 200; titanium dioxide; propylene glycol; hypromellose; ethylcellulose

관리 경로:

Oral

패키지 단위:

15, 90(E), 3 tablets, 30

수업:

Medicine Registered

처방전 유형:

(S4) Prescription Only Medicine, Not scheduled. Not considered by committee

치료 징후:

AUGMENTIN is indicated in the treatment of the following infections when caused by AUGMENTIN sensitive, beta-lactamase producing organisms: Skin and Skin Structure Infections, including cases caused by beta-lactamase producing S. aureus, E. coli and Klebsiella spp. (only some strains may be sensitive). Urinary Tract Infections, including cases caused by beta-lactamase producing E. coli, P. mirabilis & Klebsiella spp. Upper Respiratory Tract Infections, such as sinusitis, including cases caused by beta-lactamase producing H.influenzae and M.catarrhalis, and otitis media, especially cases caused by beta-lactamase producing H. influenzae, M. catarrhalis and S. aureus. Lower Respiratory Tract Infections, especially cases caused by beta-lactamase producing H.influenzae and M.catarrhalis. Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to AUGMENTIN. However, when there is reason to believe an infection may involve any

제품 요약:

Visual Identification: white, oval biconvex tablet approx 16mm in length embossed with Augmentin on one side; Container Type: Blister Pack; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius

승인 상태:

Registered

승인 날짜:

1991-08-14